Enliven Therapeutics, Inc. (ELVN) Market Cap
Enliven Therapeutics, Inc. has a market capitalization of $3.92B.
Price: $54.81
▲ 0.86 (1.59%)
Market Cap: 3.92B
NASDAQ · time unavailable
CEO: Richard A. Fair
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2020-03-12
Website: https://www.enliventherapeutics.com
Enliven Therapeutics, Inc. (ELVN) - Company Information
Market Cap: 3.92B|Sector: Healthcare
Company Profile
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Analyst Sentiment
From 10 Active Polls
1Y Forecast: $70.80
▲ +29.2% Potential Upside
Consensus Target Metrics
Low Bound
$62
Median
$67
High Bound
$80
Average
$71
Price & Moving Averages
🎯 Wall Street Analyst Intelligence Report
1-Year structural target targets, chart projections, and sentiment maps.
Consensus Trend Projection
Trailing closures vs. 12-month metrics map.
Analyst Vote Distribution
Aggregate institutional coverage sentiment weights.
📊 Historical Valuation Multiples
Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.
| Fiscal Quarter | TTM | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Period Ending | Trailing 12M | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 |
| Market Cap ($M) | 3,916 | 2,462 | 873 | 1,271 | 1,045 | 985 | 1,122 | 1,233 | 1,091 |
| Enterprise Value ($M) | 3,784 | 2,330 | 774 | 1,170 | 926 | 884 | 998 | 1,132 | 995 |
| Price to Earnings Ratio (P/E) | -33.42 | -25.79 | -8.56 | -15.99 | -10.23 | -8.63 | -12.23 | -13.30 | -13.84 |
| Price/Earnings-to-Growth Ratio (PEG) | — | — | — | — | — | — | — | — | — |
| Price to Sales Ratio (P/S) | — | — | — | — | — | — | — | — | — |
| Price to Book Ratio (P/B) | 7.59 | 5.43 | 1.90 | 2.67 | 2.14 | 3.42 | 3.62 | 4.27 | 3.58 |
| Price to Free Cash Flow Ratio (P/FCF) | -59.69 | -127.61 | -55.10 | -95.73 | -60.78 | -40.79 | -65.21 | -100.92 | -53.40 |
| Enterprise Value to Sales (EV/Sales) | — | — | — | — | — | — | — | — | — |
| Enterprise Value to EBITDA (EV/EBITDA) | -38.38 | -98.67 | -26.13 | -58.24 | -36.68 | -31.04 | -43.19 | -49.06 | -50.64 |
| Debt to Equity Ratio | 1.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
📰 Market News & Coverage
15 Stories AvailableReal-time institutional reporting and market updates for ELVN.
Enliven Therapeutics, Inc. $ELVN is Avidity Partners Management LP’s 6th Largest Position
Avidity Partners Management LP increased its stake in Enliven Therapeutics, Inc. (NASDAQ: ELVN) by 185.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 400,000 shares of the company's stock after purchasing an additional 259,700 shares during the quarter. Enliven Therapeutics makes
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical progress.
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
Orbimed Advisors reported selling 860,123 shares of ELVN on June 22, 2026, generating a transaction value of approximately $39.0 million at an average price of $45.36 per share. This transaction represented 11.60% of Advisors Llc Orbimed's total indirect holdings, reducing indirect ownership from 7,415,225 to 6,555,102 shares.
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven's common stock less the $0.001 per share exercise price for each pre-funded warrant.
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PR Newswire
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced upsized underwritten public offering of 8,933,334 shares of its common stock at a price to the public of $37.50 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,733,333 shares of Enliven's common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven's common stock less the $0.001 per share exercise price for each pre-funded warrant.
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock.
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort 67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 prior unique TKIs Favorable safety and tolerability profile with 161 patients enrolled and a median treatment duration of 35 weeks Alignment with the FDA on 80 mg QD as the recommended Phase 3 dose and on the 2L+ patient population for the ENABLE-2 pivotal trial, which is expected to initiate in the second half of this year BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today presented updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia (CML).
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
Enliven will host a webcast conference call on June 11, at 8:30 a.m. ET BURLINGAME, Calif.
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.
This oncology-focused biotech, advancing kinase inhibitors for cancer, reported a notable insider sale amid strong one-year stock gains.
Enliven Therapeutics to Present at Upcoming Investor Conferences
BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences: TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHAFormat: Fireside ChatDate: Wednesday, May 27Time: 2:30 p.m.
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials.
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-00
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously received asciminib, cumulative MMR rate was 52%, with 38% of patients achieving MMR by 24 weeks ELVN-001 maintained a favorable safety and tolerability profile with 141 patients enrolled and a median treatment duration of ~32 weeks EHA presentation will include updated data with additional patients and longer treatment duration BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced additional, positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) in an abstract accepted for an oral presentation at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden and virtually.
Related Companies in Healthcare
DOXIMITY INC CLASS A (DOCS)
Healthcare
$3.91B
Mkt Cap
HAEMONETICS CORP (HAE)
Healthcare
$3.89B
Mkt Cap
CATALYST PHARMACEUTICALS INC (CPRX)
Healthcare
$3.85B
Mkt Cap
IRHYTHM TECHNOLOGIES INC (IRTC)
Healthcare
$3.85B
Mkt Cap
CONCENTRA GROUP HOLDINGS PARENT IN (CON)
Healthcare
$4.05B
Mkt Cap
LIFESTANCE HEALTH GROUP INC (LFST)
Healthcare
$4.06B
Mkt Cap
📊 AI Financial Analysis
Powered by StockMarketInfo"Headline (2026-03-31, Q1): Revenue $0; Net income -$23.6M (EPS -$0.38). YoY (vs 2025-03-31): Net loss narrowed (from -$28.5M to -$23.6M), an improvement of ~17.2%, while EPS improved from -$0.57 to -$0.38. QoQ (vs 2025-12-31): Net loss also improved ~20.4% (from -$29.7M to -$23.6M). Margins: revenue-based margins were not meaningful as revenue was reported as $0; however, operating losses eased QoQ and YoY, consistent with some cost/interest offset improvements. Cash flow and balance sheet: Operating cash flow was -$19.3M in Q1 2026, improving vs -$15.8M in Q4 2025 (more negative QoQ), but still in line with persistent operating burn. The company ended the quarter with $132.2M cash and $320.2M short-term investments ($452.4M cash + ST investments), indicating strong liquidity. Net debt is negative (net cash position), with no meaningful debt load. Total equity was $453.4M, broadly stable/improving vs $459.6M in Q4 2025. Shareholder returns: Stock price closed at $48.11, up +199.4% over 1 year (>20% momentum), with no dividend and no disclosed buybacks in the provided cash flow. Valuation sentiment appears speculative/early-stage, supported by analyst targets around $59 (moderate upside vs $48). Revenue and Earnings-based metrics were not applicable for this analysis due to the company's pre-revenue status. The evaluation focused on cash runway, burn rate, and market sentiment instead."
Revenue Growth
Revenue was reported as $0 in all quarters provided, so no growth trajectory is observable.
Profitability
Net loss improved YoY (~17.2% less negative) and QoQ (~20.4% less negative). EPS improved from -$0.57 (2025-03-31) to -$0.38 (2026-03-31). Revenue-based margins were not meaningful due to $0 revenue.
Cash Flow Quality
Operating cash flow was -$19.3M (Q1 2026) vs -$15.8M (Q4 2025), indicating burn remains. No dividends; buybacks not evident in cash flow.
Leverage & Balance Sheet
Very low leverage: no meaningful debt; net debt is negative (net cash). Liquidity is strong with $452.4M cash + short-term investments and current ratio ~40.3x.
Shareholder Returns
Total return tailwind from strong market momentum: +199.4% 1y_change. Dividend = 0 and no repurchases shown, so appreciation is the driver.
Analyst Sentiment & Valuation
Consensus target is $59 vs $48.11 current (moderate upside). With heavy losses and pre-revenue operations, valuation likely depends on future commercialization rather than fundamentals.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Fundamentals Overview
📋 Official Regulatory 10-K / 10-Q SEC Filings
Direct authenticated documentation links to audited SEC database reports for ELVN.